Elevated folic acid results in contrasting cancer cell line growth with implications for mandatory folic acid fortification.
- Author:
Zoe YATES
1
;
Mark LUCOCK
;
Martin VEYSEY
;
Jeong Hwa CHOI
Author Information
- Publication Type:In Vitro ; Original Article
- Keywords: folate; Caco-2; MCF7; DHFR; folic acid fortification
- MeSH: Caco-2 Cells; Cell Line*; Cell Proliferation; Folic Acid*; Genetic Variation; Genotype; Humans; Incidence; Polymorphism, Restriction Fragment Length; Tetrahydrofolate Dehydrogenase
- From:Journal of Nutrition and Health 2016;49(2):72-79
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The initiation of mandatory folic acid fortification using pteroylmonoglutamic acid (PteGlu) has reduced the rate of congenital malformations. However, it also appears to be responsible for several adverse effects, including increased cancer incidence. This may be related to physicho-chemical characteristics of PteGlu. This study examines the potential effect of high concentrations of PteGlu on a population subjected to mandatory folic acid fortification using an in vitro model. METHODS: Caco-2 (colorectal cancer) and MCF7 (breast cancer) cell lines were cultured at 6 different PteGlu concentrations (0, 0.1, 1, 50, 250, and 500µg/ml) for 6 days. Cell growth was determined using thiazolyl blue tetrazolium bromide assay. The genotype of dihydrofolate reductase 19bp deletion/insertion (DHFR 19-del) was also scored in cell lines using a restriction fragment length polymorphism technique to examine whether genetic variations may factor in cell proliferation. RESULTS: PteGlu exhibited differential growth promoting properties between cell lines. Caco-2 cells did not show a significant growth difference at low concentrations compared to control, however, at higher concentrations, the growth showed a contrasting trend in the early experimental period, while MCF7 showed enhanced cell growth at all concentrations. The DHFR 19-del genotype differed in the two cell lines. CONCLUSION: Altered response to PteGlu by Caco-2 and MCF7 may reflect a tissue specific disease aetiology or genotype specific differential enzyme activity, for example by DHFR, to critical levels of PteGlu. As folic acid fortification is a blanket intervention, and DHFR and other enzyme activities vary between individuals, PteGlu intake may have an as yet undefined effect on health. These findings may be relevant when considering mandatory folic acid fortification for disease prevention.
